How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,005 results for

Androgenic Alopecia

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

301. Polycystic ovary syndrome: Scenario: Management of polycystic ovary syndrome in adults

-term of PCOS. Advise women who are overweight or obese that weight loss may reduce hyperandrogenism. See the CKS topic on for more information. Discuss methods of hair reduction and removal (such as shaving and waxing), as these will remain an important part of management. See the CKS topic on for more information. Consider prescribing a COC, provided there are no contraindications. See the CKS topic on for prescribing information on COCs, including contraindications and cautions, choice, risks (...) Society Policy and Practice Guidelines is that a loss of more than 5% in body weight can be enough to restore fertility and improve metabolic markers [ ]. Choice of treatment COCs are the mainstay of the pharmacological treatment of PCOS as they can be used to manage both menstrual disorders and androgen excess symptoms (such as acne and hirsutism). Progestogens, usually given cyclically, also have a role in the management of menstrual dysfunction [ ]. The International PCOS Network advises

2018 NICE Clinical Knowledge Summaries

302. Amenorrhoea: How should I assess for an underlying cause of secondary amenorrhoea?

an eating disorder or the ). Examine for features of: Cushing's syndrome (striae, buffalo hump, significant central obesity, easy bruising, hypertension, and proximal muscle weakness). Thyroid disease. See the CKS topics on and for more information. Excess androgens (hirsutism, acne) or virilization (hirsutism, acne, deep voice, temporal balding, increase in muscle bulk, breast atrophy, and clitoromegaly). Decreased endogenous estrogen (reddened or thin vaginal mucosa). If appropriate, examine (...) gain (suggesting polycystic ovary syndrome [PCOS]). Stress, depression, weight loss, disturbance of perception of weight or shape, level of exercise, and chronic systemic illness (suggesting hypothalamic dysfunction). Symptoms of thyroid and other endocrine disease. A history of obstetric or surgical procedures (such as endometrial curettage) that may have resulted in intrauterine adhesions. A history of chemotherapy and pelvic radiotherapy (which can cause POI); and cranial radiotherapy, head

2018 NICE Clinical Knowledge Summaries

303. Amenorrhoea: How should I assess for an underlying cause of primary amenorrhoea?

raised prolactin). Haematocolpos if there is a history of cyclical lower abdominal pain (separation of the labia reveals a bulging, blue-coloured membrane, and a pelvic mass may be palpable). Features of decreased endogenous oestrogen (reddened or thin vaginal mucosa; breast development is a good marker for ovarian oestrogen production). Features of androgen insensitivity (absence of axillary and pubic hair with normal breast development; testes may be palpable in the inguinal canal or labia (...) an intracranial lesion for example, hydrocephalus. Normal height and high FSH and LH levels suggest ovarian failure (normal karyotype) or 46XY (abnormal karyotype). Normal height and low FSH and LH levels suggest constitutional delay, weight loss, anorexia nervosa, or excessive exercise. Total testosterone levels High levels of total testosterone (5.0 nanomol/L or greater) warrant investigation to exclude androgen insensitivity (46XY genotype, female phenotype), late-onset congenital adrenal hyperplasia

2018 NICE Clinical Knowledge Summaries

304. Acne clinical guideline Full Text available with Trip Pro

, A. Hormonal profiles and prevalence of polycystic ovary syndrome in women with acne. J Dermatol . 1997 ; 24 : 223–229 | | , x 53 Lucky, A.W. Endocrine aspects of acne. Pediatr Clin North Am . 1983 ; 30 : 495–499 | , x 54 Lucky, A.W., McGuire, J., Rosenfield, R.L., Lucky, P.A., and Rich, B.H. Plasma androgens in women with acne vulgaris. J Invest Dermatol . 1983 ; 81 : 70–74 | | | , x 55 Abulnaja, K.O. Changes in the hormone and lipid profile of obese adolescent Saudi females with acne vulgaris. Braz J Med (...) : 25–33 | | | | | Spironolactone B II, III x 102 Shaw, J.C. Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. J Am Acad Dermatol . 2000 ; 43 : 498–502 | | | | , x 103 Sato, K., Matsumoto, D., Iizuka, F. et al. Anti-androgenic therapy using oral spironolactone for acne vulgaris in Asians. Aesthetic Plast Surg . 2006 ; 30 : 689–694 | | | Flutamide C III x 104 Wang, H.S., Wang, T.H., and Soong, Y.K. Low dose flutamide

2016 American Academy of Dermatology

305. Preventing and Experiencing Ischemic Heart Disease as a Woman: State of the Science Full Text available with Trip Pro

, and hair texture) that imposes social concerns. Interestingly, racial/ethnic variations in IHD exist in the United States, and black women have higher prevalence rates (7.0%) of IHD compared with Hispanic (5.9%) and white (4.6%) women. The same trend is noted with myocardial infarction (2.2%, 1.7%, and 1.8%, respectively) and angina (5.0%, 3.8%, and 2.9%). The AHA statistical data for Asian and American Indian/Alaska Native women either are not listed or did not meet the standards of reliability (...) of HRT, the dose of HRT, or the preparation of the HRT itself may play a role in the efficacy. For example, conjugated equine estrogen is a common estrogenic HRT, but because of the source (urine of pregnant mares), there are a significant number of other steroids in the preparation such as androgens. Conjugated equine estrogen was the preparation used in the WHI. Ichikawa and colleagues found that transdermal HRT for 12 and 24 months reduced diastolic and mean BPs in normotensive postmenopausal

2016 American Heart Association

308. Systematic review of needs for medical devices for ageing populations

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .86 6.3.1 Adult-onset hearing loss. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .86 Table 40 Hearing loss – key studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .88 Table 41 Hearing loss – devices identified for diagnosis and treatment . . . . . . . . . . . . . . . . . . . . . . . .88 6.4 CONCLUSION. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .90 7. NEUROPSYCHIATRIC CONDITIONS (...) burdens on the provision of health care services to this demographic. Many medical devices are available that may benefit elderly people, although these devices may be expensive or may not be available in all countries. These factors impede equitable access to medical devices. The clinical focus of this report has been defined as the five health conditions that cause the greatest loss of disability-adjusted life-years (DALYs) for older people (defined as people aged 60–79 years) in the Western Pacific

2015 Publication 80

310. ACS/ASCO Breast Cancer Survivorship Care Guideline Full Text available with Trip Pro

as indicated (LOE = IA). Lymphedema Recommendation 3.2: It is recommended that primary care clinicians (a) should counsel survivors on how to prevent/reduce the risk of lymphedema, including weight loss for those who are overweight or obese (LOE = 0); and (b) should refer patients with clinical symptoms or swelling suggestive of lymphedema to a therapist knowledgeable about the diagnosis and treatment of lymphedema, such as a physical therapist, occupational therapist, or lymphedema specialist (LOE = 0 (...) and maintain a healthy weight (LOE = III); and (b) should counsel survivors if overweight or obese to limit consumption of high-calorie foods and beverages and increase physical activity to promote and maintain weight loss (LOE = IA, III). Physical activity Recommendation 4.3: It is recommended that primary care clinicians should counsel survivors to engage in regular physical activity consistent with the ACS guideline (Rock 2012 23 ) and specifically: (a) should avoid inactivity and return to normal daily

2015 American Society of Clinical Oncology Guidelines

311. Menopausal Symptoms: Comparative Effectiveness of Therapies

a third reviewer. Study quality of RCTs was assessed by assembly of comparable groups, blinding of researchers and subjects, concealment of group assignment, maintenance of comparable groups, differential loss to followup, equal and reliable measurements, clearly defined interventions, important outcomes considered and defined, and intention-to-treat analysis. ES-6 Study quality of cohort studies was assessed by assembly of comparable groups, maintenance of comparable groups, differential loss

2015 Effective Health Care Program (AHRQ)

312. Long-term Consequences Polycystic Ovary Syndrome

to be an association with breast or ovarian cancer and no additional surveillance is required. Strategies for reduction of risk Exercise and weight control How should women with PCOS be advised on lifestyle issues? It is recommended that lifestyle changes, including diet, exercise and weight loss, are initiated as the first line of treatment for women with PCOS for improvement of long-term outcomes and should precede and/or accompany pharmacological treatment. Is drug therapy appropriate for long-term management (...) for selected anovulatory patients, especially those with a normal BMI, as an alternative to ovulation induction. Bariatric surgery What is the prognosis following bariatric surgery? Bariatric surgery may be an option for morbidly obese women with PCOS (BMI of 40 kg/m 2 or more or 35 kg/m 2 or more with a high-risk obesity-related condition) if standard weight loss strategies have failed. C P A C C C P B B C1. Purpose and scope This guideline aims to provide information, based on clinical evidence

2014 Royal College of Obstetricians and Gynaecologists

314. A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer. Full Text available with Trip Pro

A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer. Results from randomized phase III trials have shown that thrice-weekly docetaxel added to androgen-deprivation therapy (ADT) has a significant impact on the survival of patients with metastatic castration-naïve prostate cancer (mCNPC) and established early chemotherapy as part of the standard of care for high-risk disease. Controversy remains, however, because some (...) occurred. High-risk was defined as bone metastases beyond axial skeleton and/or visceral disease.The included patients' median age was 68 years (range: 31-86 years) and 17 (49%) had visceral metastases. Biweekly docetaxel was generally well-tolerated; the most commonly observed adverse events, considering those of all grades, included alopecia (74%), nail changes (42%), and constipation (31%). Hematologic adverse events were infrequent, and no patient received hematopoietic growth factors. One patient

2019 BMC Urology Controlled trial quality: uncertain

315. Optimizing live-animal bioluminescence imaging prediction of tumor burden in human prostate cancer xenograft models in SCID-NSG mice. (Abstract)

mice through intraprostatic (orthotopic) and subcutaneous (SC) inoculations revealed either nonexistent or poor correlation (coefficient of determination, R 2  = ~0.01-0.3). The present work examined several technical and biological factors to improve BLI utility.After ruling out promoter-luciferase (luc) specificity and luc gene loss in the cell inoculum with LNCaP-AR-luc cells expressing an androgen receptor (AR) and tagged with AR-responsive probasin promoter-luc gene, we evaluated different (...) Optimizing live-animal bioluminescence imaging prediction of tumor burden in human prostate cancer xenograft models in SCID-NSG mice. Noninvasive live-animal longitudinal monitoring of xenograft tumor growth and metastasis by bioluminescent imaging (BLI) has been widely reported in cancer biology and preclinical therapy literature, mainly in athymic nude mice. Our own experience at calibrating BLI readout with tumor weight/volume in human prostate cancer xenograft models in haired, SCID-NSG

2019 Prostate

316. Cholesterol homeostasis: links to hair follicle biology and hair disorders. Full Text available with Trip Pro

Cholesterol homeostasis: links to hair follicle biology and hair disorders. Lipids and lipid metabolism are critical factors in hair follicle (HF) biology and cholesterol has long been suspected of influencing hair growth. Altered cholesterol homeostasis is involved in the pathogenesis of primary cicatricial alopecia, mutations in a cholesterol transporter are associated with congenital hypertrichosis and dyslipidaemia has been linked to androgenic alopecia. The underlying molecular mechanisms (...) by which cholesterol influences pathways involved in proliferation and differentiation within HF cell populations remains largely unknown. As such, expanding our knowledge of the role for cholesterol in regulating these processes is likely to provide new leads in the development of treatments for disorders of hair growth and cycling. This review describes the current state of knowledge with respect to cholesterol homeostasis in the HF along with known and putative links to hair pathologies

2019 Experimental Dermatology

317. Bacillus/Trapa japonica Fruit Extract Ferment Filtrate enhances human hair follicle dermal papilla cell proliferation via the Akt/ERK/GSK-3β signaling pathway. Full Text available with Trip Pro

Bacillus/Trapa japonica Fruit Extract Ferment Filtrate enhances human hair follicle dermal papilla cell proliferation via the Akt/ERK/GSK-3β signaling pathway. Despite advances in medical treatments, the proportion of the population suffering from alopecia is increasing, creating a need for new treatments to control hair loss and prevent balding. Treatments based on plant-derived compounds could potentially prevent hair loss. Human hair follicle dermal papilla (HDP) cells, a type of specialized (...) fibroblast in the hair bulb, play an essential role in controlling hair growth and in conditions such as androgenic alopecia. We examined the effect of Bacillus/Trapa japonica fruit ferment filtrate extracts (TJFs) on HDP cells to determine whether activation of the Akt/ERK/GSK-3β signaling pathway improved HDP cell proliferation.We prepared TJFs using various methods. The extract properties were analyzed using WST-1, Lowry, and cell migration assays as well as immunofluorescence staining. We also

2019 BMC Complementary and Alternative Medicine

318. Jarilla-Coffea extract: a natural cosmetic product that improves eyelash and eyebrow growth in women. Full Text available with Trip Pro

Jarilla-Coffea extract: a natural cosmetic product that improves eyelash and eyebrow growth in women. A combination of extracts, from two plant species, ie, Coffea arabica and Larrea divaricata (Jarilla) (ECOHAIR®), is being successfully used in Argentina as a cosmetic for hair recovery in androgenic and areata alopecia, and for eyelash and eyebrow growth. The objectives of this prospective study were to evaluate the capacity of Jarilla-Coffea extract gel of improving hair growth in relation (...) to thickness, appearance of new hair, and hair length in comparison with a placebo in premenopausal and postmenopausal volunteers and to identify possible signs of ocular adverse local reactions related to the application of the gel.An open-label, placebo-controlled, prospective study was performed in healthy premenopausal and postmenopausal women during a daily administration period of 2 months (eyebrow growth) and 3 months (eyelash growth). The thickness of hair was determined using a video microscope

2019 Clinical, cosmetic and investigational dermatology Controlled trial quality: uncertain

319. Evaluating hair growth promoting effects of candidate substance: A review of research methods. Full Text available with Trip Pro

Evaluating hair growth promoting effects of candidate substance: A review of research methods. Androgenetic alopecia (AGA) is the most common form of hair loss disorder. As the prevalence of AGA rises, the demand for AGA treatments is rising accordingly, prompting research to identify therapeutic candidates to treat AGA. Because AGA is caused by crosstalk among multiple hair follicle (HF) cell components, understanding the effects of candidate molecules on HF cells is essential to determining (...) . The main outcomes used to evaluate the effects of candidate substances are 1) changes in HF growth rates in vitro, 2) anagen induction capabilities, and 3) the effects of androgen modulation. This article reviews a series of methods used to evaluate the hair growth-promoting effects of candidate substances, providing an overview of cell assays, organs, and animal models used in AGA research in order to facilitate AGA research moving forward.Copyright © 2019 The Author(s). Published by Elsevier B.V. All

2019 Journal of dermatological science

320. Xtandi - enzalutamide

and unfavourable effects 84 Benefit-risk balance 84 Discussion on the benefit-risk balance 85 4. Recommendations 85 Xtandi CHMP assessment report EMA/CHMP/383457/2013 Page 5/86 List of abbreviations ALP alkaline phosphatase ALT alanine aminotransferase AR Androgen Receptor AST alanine aminotransferase AUC Area Under the Curve AUC inf Area Under the Curve Extrapolated Based on the Elimination Rate Constant BCS BHA BHT Bic BUN CCMG CEP Biopharmaceutics Classification System Butylated hydroxyanisole Butylated (...) Results of clinical investigations and studies on the molecular profiles of these progressing prostate tumours show that the androgen receptor remains functional and that the tumours should respond to strategies directed at the androgen receptor signalling axis. Over-expression of the androgen receptor has been documented in upwards of 50% of castration-resistant prostate cancer specimens and is believed to contribute to tumour progression (Pienta, 2006, Chen, 2004). Currently approved anti- androgens

2013 European Medicines Agency - EPARs

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>